Cooley advised Arena Pharmaceuticals on its global license agreement with United Therapeutics for Arena’s drug candidate ralinepag, a next-generation treatment of pulmonary arterial hypertension (PAH). Arena…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
